Bob

Muscle Cell News

Molecular Basis of Muscle Wasting and Emerging Therapeutic Strategies Targeting Degenerative Muscle Disorders

[Experimental Cell Research] Scientists summarize current knowledge of the molecular mechanisms underlying muscle degeneration and discusses emerging therapeutic strategies that hold promise for effective muscle regeneration.

Intestinal Cell News

Sabotaging Cancer Could Open Doors to New Treatments

[The University of Edinburgh] Researchers at the University of Edinburgh’s Institute of Genetics and Cancer are launching a £1.5 million Cancer Research UK-funded study to find a way to ‘trick’ bowel cancer cells.

Intestinal Cell News

CGF Induces ROS-Mediated Metabolic Reprogramming and Mitochondrial Dysfunction to Suppress Colorectal Cancer Progression

[iScience] Using colorectal cancer cell lines, organoids, and xenograft models, investigators showed that Cya-Gly-Fer (CGF) significantly inhibits tumor growth and metastasis.

Intestinal Cell News

Bacterial Protein-Oleate Complexes Induce Ferroptosis-Like Cell Death in Colorectal Cancer Cells by Disrupting Cell Membranes and Inhibiting the β-Catenin-GPX4 Axis

[Cell Death Discovery] Investigators demonstrated that α-helical proteins of bacterial origin can form tumoricidal complexes with sodium oleate.

Intestinal Cell News

Carbohydrate Responsive Element Binding Protein Promotes Colorectal Carcinogenesis via Wnt/β-Catenin Pathway

[Oncogene] The authors used the azoxymethane/dextran sulfate sodium model to induce colorectal cancer and investigate the role of carbohydrate response element-binding proteinin colorectal carcinogenesis in vivo.

Intestinal Cell News

Notch Signaling Governs Colorectal Cancer Metastasis via Transcriptional Control of TGF-β Effectors SMAD2/SMAD3

[British Journal of Cancer] Scientists investigated the hypothesis that Notch signaling, through RBP-J, directly transcriptionally regulates SMAD2 and SMAD3, thereby modulating transforming growth factor-beta (TGF-β) pathway output.

123...692 Page 2 of 692

Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases

[Asahi Kasei] Asahi Kasei announced the initiation of a Phase I clinical trial for AK1940, a novel peptide-based investigational compound developed to address significant unmet medical needs in patients with autoimmune diseases.

FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

[Genentech] Genentech announced that the US FDA has accepted the company’s supplemental Biologics License Application for Gazyva® for the treatment of systemic lupus erythematosus.

Low Dose IL-2 Therapy Restores Regulatory T Cells in Patients with Systemic Lupus Erythematosus in a Dose-Dependent Manner: A Phase IIb Trial

[Nature Communications] In this multicenter, double-blind, Phase IIb trial, 152 patients with active systemic lupus erythematosus were randomized to receive subcutaneous interleukin 2 or placebo every other day for 12 weeks, then weekly for another 12 weeks. Low-dose-IL2 drove the expansion of Tregs and altered Treg/effector T cell ratios.

All Articles by Author:

Bob

Popular